NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. (3rd October 2021)

• Record Type: Journal Article
• Authors: Trombetta, Domenico; Sparaneo, Angelo; Fabrizio, Federico Pio; Di Micco, Concetta Martina; Rossi, Antonio; Muscarella, Lucia Anna
• Is Part Of: Expert opinion on therapeutic targets. Volume 25:Number 10(2021)
• Page Start: 865
• Page End: 875
• Publication Date: 2021-10-03
• Subjects: NRG1 -- NRG2 -- gene fusion -- TKR -- target therapy -- IMA -- NSCLC; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2021.1999927
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Fusions in neuregulin 1 ( NRG1 ) and neuregulin 2 ( NRG2 ) genes are molecular features of non-small cell lung cancer (NSCLC). These rearrangements enhance ectopic expression of the NRG/ErbB receptor‐ligand and induce the triggering of downstream pathways. Evidence suggests the involvement of the NRG1/ErbB3 axis deregulation in the progression and treatment resistance of NSCLC cancer (NSCLC) and that NRG1 fusions are prognostic/predictive markers for targeted therapy. Areas covered: Biological and prognostic/predictive value of NRG1 and NRG2 fusions in NSCLC and their related cellular pathways are described and discussed. Publications in English language, peer-reviewed, high-quality international journals were identified on PubMed, as well as scientific official sites were used to update the international clinical trials progress. Expert Opinion: NRG1 and NRG2 fusions should be considered as novel markers for biological therapy targeting ErbB2/ErbB3. There is evidence for the involvement of the NRG1/ErbB3 axis deregulation in cancer stem cell phenotype, tumor progression, and resistance to NSCLC therapy. Neuregulin fusions are very complex, hence many question marks must be tackled before translating these molecular lesions into clinical practice. Biology, and aggressiveness of the NRG1 and NRG2 fusions warrant further investigations.